Revealed: 3 Stocks for Potentially Massive Gains
Here is the latest financial fact sheet of ALEMBIC. For more details, see the ALEMBIC quarterly results and ALEMBIC share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | -4.2 |
No. of shares | m | 553.80 |
% ch week | % | -4.3 |
% ch 1-mth | % | 0.6 |
% ch 12-mth | % | 123.0 |
52 week H/L | Rs | 122.8/43.5 |
No. of Mths Year Ending |
12 Mar-14 |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
---|
ALEMBIC EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 18 | 70 | 53 | 46 | 72 | |
Low | Rs | 7 | 16 | 29 | 32 | 34 | |
Sales per share (Unadj.) | Rs | 5.8 | 5.4 | 4.7 | 5.3 | 4.7 | |
Earnings per share (Unadj.) | Rs | 1.1 | 4.0 | 8.8 | 5.4 | 6.1 | |
Diluted earnings per share | Rs | 0.5 | 1.9 | 4.2 | 2.6 | 2.9 | |
Cash flow per share (Unadj.) | Rs | 1.2 | 4.2 | 9.0 | 5.6 | 6.2 | |
Dividends per share (Unadj.) | Rs | 0.15 | 0.15 | 0.15 | 0.20 | 0.20 | |
Adj. dividends per share | Rs | 0.07 | 0.07 | 0.07 | 0.10 | 0.10 | |
Dividend yield (eoy) | % | 1.2 | 0.3 | 0.4 | 0.5 | 0.4 | |
Book value per share (Unadj.) | Rs | 8.6 | 19.8 | 27.7 | 34.1 | 40.7 | |
Adj. book value per share | Rs | 4.2 | 9.5 | 13.4 | 16.5 | 19.6 | |
Shares outstanding (eoy) | m | 267.03 | 267.03 | 267.03 | 267.03 | 267.03 | |
Bonus/Rights/Conversions | B1:1 | - | - | - | - | ||
Price / Sales ratio | x | 2.1 | 8.0 | 8.7 | 7.5 | 11.3 | |
Avg P/E ratio | x | 11.2 | 10.8 | 4.7 | 7.2 | 8.7 | |
P/CF ratio (eoy) | x | 10.4 | 10.2 | 4.6 | 7.0 | 8.5 | |
Price / Book Value ratio | x | 1.4 | 2.2 | 1.5 | 1.2 | 1.3 | |
Dividend payout | % | 13.6 | 3.8 | 1.7 | 3.7 | 3.3 | |
Avg Mkt Cap | Rs m | 3,298 | 11,469 | 10,962 | 10,521 | 14,139 | |
No. of employees | `000 | NA | NA | NA | NA | NA | |
Total wages/salary | Rs m | 273 | 270 | 238 | 228 | 207 | |
Avg. sales/employee | Rs Th | NM | NM | NM | NM | NM | |
Avg. wages/employee | Rs Th | NM | NM | NM | NM | NM | |
Avg. net profit/employee | Rs Th | NM | NM | NM | NM | NM |
ALEMBIC INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 1,536 | 1,439 | 1,260 | 1,403 | 1,255 | |
Other income | Rs m | 158 | 208 | 264 | 310 | 370 | |
Total revenues | Rs m | 1,694 | 1,647 | 1,524 | 1,713 | 1,625 | |
Gross profit | Rs m | 223 | 95 | 83 | 67 | 111 | |
Depreciation | Rs m | 23 | 60 | 61 | 51 | 38 | |
Interest | Rs m | 23 | 8 | 0 | 2 | 2 | |
Profit before tax | Rs m | 335 | 235 | 285 | 324 | 442 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 825 | 2,096 | 1,179 | 1,212 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | -32 | -58 | 0 | |
Tax | Rs m | 39 | -7 | 6 | -9 | 24 | |
Profit after tax | Rs m | 295 | 1,066 | 2,343 | 1,454 | 1,630 | |
Gross profit margin | % | 14.5 | 6.6 | 6.6 | 4.8 | 8.9 | |
Effective tax rate | % | 11.8 | -2.9 | 2.1 | -2.6 | 5.4 | |
Net profit margin | % | 19.2 | 74.1 | 185.9 | 103.6 | 129.8 |
ALEMBIC BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 1,543 | 1,609 | 1,689 | 1,913 | 1,867 | |
Current liabilities | Rs m | 907 | 533 | 486 | 683 | 591 | |
Net working cap to sales | % | 41.4 | 74.8 | 95.4 | 87.6 | 101.6 | |
Current ratio | x | 1.7 | 3.0 | 3.5 | 2.8 | 3.2 | |
Inventory Days | Days | 248 | 214 | 217 | 132 | 94 | |
Debtors Days | Days | 66 | 122 | 81 | 56 | 74 | |
Net fixed assets | Rs m | 1,800 | 1,715 | 1,624 | 1,716 | 1,791 | |
Share capital | Rs m | 534 | 534 | 534 | 534 | 534 | |
"Free" reserves | Rs m | 874 | 3,839 | 5,960 | 8,580 | 10,324 | |
Net worth | Rs m | 2,307 | 5,278 | 7,404 | 9,114 | 10,858 | |
Long term debt | Rs m | 331 | 354 | 104 | 18 | 41 | |
Total assets | Rs m | 3,562 | 6,192 | 8,010 | 9,924 | 11,591 | |
Interest coverage | x | 15.4 | 29.3 | 950.7 | 203.8 | 260.9 | |
Debt to equity ratio | x | 0.1 | 0.1 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.4 | 0.2 | 0.2 | 0.1 | 0.1 | |
Return on assets | % | 8.9 | 17.4 | 29.3 | 14.7 | 14.1 | |
Return on equity | % | 12.8 | 20.2 | 31.6 | 16.0 | 15.0 | |
Return on capital | % | 13.6 | 19.0 | 31.3 | 15.8 | 15.2 | |
Exports to sales | % | 7.7 | 14.3 | 2.9 | 0.7 | 1.5 | |
Imports to sales | % | 3.4 | 2.5 | 28.9 | 25.4 | 21.0 | |
Exports (fob) | Rs m | 118 | 205 | 37 | 10 | 19 | |
Imports (cif) | Rs m | 52 | 37 | 364 | 356 | 263 | |
Fx inflow | Rs m | 118 | 205 | 37 | 10 | 19 | |
Fx outflow | Rs m | 63 | 42 | 365 | 357 | 264 | |
Net fx | Rs m | 55 | 163 | -328 | -346 | -244 |
ALEMBIC CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -102 | 220 | 346 | 516 | 236 | |
From Investments | Rs m | 178 | 47 | -48 | -467 | -224 | |
From Financial Activity | Rs m | -79 | -250 | -301 | -50 | -27 | |
Net Cashflow | Rs m | -3 | 17 | -3 | 0 | -15 |
Share Holding
|
Company Information
|
CHM: Chirayu R. Amin (MD) | COMP SEC: Chirag K. Shukla | YEAR OF INC: 1907 | BSE CODE: 506235 | FV (Rs): 2 | DIV YIELD (%): 0.1 |
More Pharmaceuticals Company Fact Sheets: BIOCON ALKEM LABORATORIES SUVEN LIFE SCIENCES DR. REDDYS LAB ALEMBIC PHARMA
Compare ALEMBIC With: BIOCON ALKEM LABORATORIES SUVEN LIFE SCIENCES DR. REDDYS LAB ALEMBIC PHARMA
Compare ALEMBIC With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today as fears that the government could go for stricter lockdowns.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More